{"id":"W1490550714","doi":"10.1002/cncr.28406","title":"Intravenous aflibercept in patients with platinum‐resistant, advanced ovarian cancer: Results of a randomized, double‐blind, phase 2, parallel‐arm study","year":2013,"lang":"en","type":"article","venue":"Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Aflibercept; Clinical endpoint; Internal medicine; Topotecan; Ovarian cancer; Cohort; Surgery; Randomized controlled trial; Phases of clinical research; Cancer; Progression-free survival; Clinical trial; Chemotherapy; Bevacizumab; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003537096,0.001415877,0.002934466,0.0004146324,0.0003247664,0.00085025,0.0006306085,0.001323708,0.002573454],"category_scores_gemma":[0.002978729,0.0007065955,0.001427028,0.0004770151,0.0008906352,0.0009768375,0.0002727427,0.001811395,0.0005452748],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006055889,"about_ca_system_score_gemma":0.001146489,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000298864,"about_ca_topic_score_gemma":0.0004688183,"domain_scores_codex":[0.9985772,0.000936801,0.00009622308,0.0001757361,0.0001008748,0.000113199],"domain_scores_gemma":[0.9980053,0.0006518339,0.0004848631,0.0002622722,0.000132052,0.0004637401],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9287852,0.02086023,0.00245182,0.0004112344,0.0008817043,0.00006651211,0.00008310954,0.0005245792,0.00641408,0.00006320097,0.0007268773,0.03873144],"study_design_scores_gemma":[0.9018109,0.09372256,0.002885518,0.00001245323,0.0002744136,0.00004916381,0.000007479991,0.0003226467,0.0004155615,0.0000477393,0.0004413636,0.00001011921],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928505,0.002415234,0.0007209902,0.0003585676,0.000206968,0.002267698,0.0004049402,0.00008082831,0.0006942078],"genre_scores_gemma":[0.9896814,0.001718474,0.002390729,0.000905401,0.0005072097,0.003095188,0.0008700719,0.00003117689,0.0008003761],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003537096,"threshold_uncertainty_score":0.01870614,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01861937080668284,"score_gpt":0.3044274961335927,"score_spread":0.2858081253269098,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}